For 2010 fourth quarter, analysts polled by Bloomberg expect the company to report earnings of 96 cents per share, compared to earnings of 10 cents per share and 9 cents per share during the year-ago and quarter-ago periods, respectively. Analysts estimate the company to report earnings per share of $1.35 cents for 2010, a significant improvement from earnings of 33 cents per share reported for 2009.
Over the past one year, the stock surged around 38%. In comparison Baxter International (BAX), Covidien (COV), C.R. Bard (BCR), and Teleflex (TFX) returned around -14%, -6%, 16%, and -2%, respectively.
All the seven analysts covering the stock recommend buying. Analysts expect the stock to gain around 34% over the next 12 months with a consensus target price of $14.9.